GamaSTAN SD
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $189,118 | 5 | 1 |
| 2018 | $951,150 | 45 | 0 |
| 2017 | $16.14 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 49 | 100.0% |
| Food and Beverage | $31.47 | 2 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Prospective, Open-Label, Single-Arm Clinical Trial to Assess the Anti-Hepatitis A Virus HAV Antibody Levels, Pharmacokinetics, and Safety of a Single Intramuscular Dose of a Polyvalent Human Immune Globulin in HAV Seronegative Healthy Subjects | Grifols Therapeutics LLC | $1.1M | 0 |
Manufacturing Companies
- Grifols Therapeutics LLC $1.1M
- Grifols USA, LLC $31.47
Product Information
- Type Biological
- Total Payments $1.1M
- Total Doctors 2
- Transactions 51
About GamaSTAN SD
GamaSTAN SD is a biological associated with $1.1M in payments to 2 healthcare providers, recorded across 51 transactions in the CMS Open Payments database. The primary manufacturer is Grifols Therapeutics LLC.
Payment data is available from 2017 to 2019. In 2019, $189,118 was paid across 5 transactions to 1 doctors.
The most common payment nature for GamaSTAN SD is "Unspecified" ($1.1M, 100.0% of total).
GamaSTAN SD is associated with 1 research study, including "A Prospective, Open-Label, Single-Arm Clinical Trial to Assess the Anti-Hepatitis A Virus HAV Antibody Levels, Pharmacokinetics, and Safety of a Single Intramuscular Dose of a Polyvalent Human Immune Globulin in HAV Seronegative Healthy Subjects" ($1.1M).